ArticlePediatric research2026
Effects of Bifidobacterium infantis M-63 on gut environment and bowel function during weaning: RCT.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWeaning involves rapid shifts in the gut microbiota, bowel irregularities, and increased infection risks. This exploratory, hypothesis-generating study examined whether daily supplementation with Bifidobacterium longum subsp. infantis M-63 (M-63) may influence bowel function, the gut environment, and general health during weaning.
methodsIn a randomized, double-blind, placebo-controlled trial, 100 healthy infants and toddlers (5 months to under 3 years) received M-63 (5 billion CFU) or placebo for eight weeks. Stool habits, fecal microbiota, and short-chain fatty acids (SCFAs) were assessed. Cold-like symptoms and medication use were recorded. Exploratory subgroup analyses considered breastfeeding status, age (<1.5 years), and the presence of siblings.
resultsM-63 supplementation was associated with more days of normal stools and a trend toward fewer diarrhea episodes. Subgroup analyses revealed that breastfed children showed increased B. infantis abundance. In contrast, non-breastfed children exhibited higher fecal SCFA levels. Children <1.5 years and those with siblings showed trends toward fewer cold-like symptoms and reduced antibiotic use. No intervention-related adverse events occurred.
conclusionsThis exploratory trial suggests M-63 may be associated with modest improvements in gastrointestinal outcomes and selected systemic health-related measures during weaning. These findings should be interpreted cautiously and require confirmation in adequately powered trials. IMPACT: Daily administration of B. infantis M-63 was associated with potential improvements in bowel habits among infants. In breastfed children, supplementation with B. infantis M-63 was associated with an observed increase in the relative abundance of B. infantis, alongside a trend toward greater bifidobacterial diversity. In non-breastfed children, B. infantis M-63 was associated with modestly elevated levels of fecal metabolites, including short-chain fatty acids. Exploratory findings suggest that supplementation with B. infantis M-63 during weaning may modulate the gut environment and may be associated with immune-related measures, but confirmation in larger, rigorously designed trials is needed.
Identifiers
42056537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.